LamdaGen Corporation, a leading developer of diagnostic biosensors, today announced it has received notification from the European Patent Office (EPO) of its intention to grant the patent application entitled "Enzymatic Assays for LSPR" which enables highly sensitive and rapid diagnostic assays.
Benitec Biopharma is pleased to announce the launch of a new exploratory cellular therapy program including exosome-based delivery utilising the Company's proprietary ddRNAi technology. Entry into these areas have been facilitated by the commencement of a collaboration with UK-based stem cell therapeutics company, ReNeuron.
New research led by scientists at The Scripps Research Institute (TSRI), International AIDS Vaccine Initiative (IAVI) and The Rockefeller University shows in mice that an experimental vaccine candidate designed at TSRI can stimulate the immune system activity necessary to stop HIV infection. The findings could provide key information for the development of an effective AIDS vaccine.
Tekmira Pharmaceuticals Corporation, an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV), today announced that the Phase II clinical trial of TKM-Ebola-Guinea has reached a predefined statistical endpoint and enrollment has been closed.
Researchers at the University of Illinois have discovered an easy method to produce carbon nanoparticles for biomedical applications. These carbon nanoparticles can be made at home within a couple of hours using easily available ingredients and molasses. Comparatively, other existing methods require days for production and also need costly purification processes and equipment.
National Institutes of Health (NIH) researchers and their colleagues have developed a "placenta-on-a-chip" to study the inner workings of the human placenta and its role in pregnancy. The device was designed to imitate, on a micro-level, the structure and function of the placenta and model the transfer of nutrients from mother to fetus. This prototype is one of the latest in a series of organ-on-a-chip technologies developed to accelerate biomedical advances.
The Florida Institute for the Commercialization of Public Research (the Institute) announced today that it has finalized a funding agreement with TransGenex Nanobiotech, Inc. (TGN), a company that is developing nano-scale technologies for novel, cost-effective diagnostic and therapeutic agents against cancers and other inflammatory diseases.
Someday, treating patients with nanorobots could become standard practice to deliver medicine specifically to parts of the body affected by disease. But merely injecting drug-loaded nanoparticles might not always be enough to get them where they need to go. Now scientists are reporting in the ACS journal Nano Letters the development of new nanoswimmers that can move easily through body fluids to their targets.
Stem cell-based therapies have the potential to transform the treatment of almost every major health condition, but possibly none quite as prevalent as heart disease. As the world’s number one cause of death, heart disease kills more than 7.5 million people each year, and its irreversible course leaves millions more dependent on devices and medications to survive.
Scientists from the Trinity College Dublin and the ITMO University have demonstrated that ordinary nanocrystals have intrinsic chirality, and this occurs due to chiral defects that take place naturally during normal nanocrystal synthesis. They have shown that the chiral nanocrystals could be produced as a half-and-half mixture under normal conditions and these would be mirror images of one another. This finding in nanocrystals has opened new possibilities in medicine, bio-technology and nanobiotechnology. In medicine it could be used for targeted delivery of drugs.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.